Series A financing at Somagenetix to advance gene therapy for chronic granulomatous disease

Oct. 9, 2024

Somagenetix AG has announced the initial closing of its series A financing round, raising CHF10 million.

BioWorld Science Financings Gene therapy Immune Series A

Today's news in brief

BioWorld

BioWorld briefs for May 20, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...

Regeneron’s fianlimab lags in melanoma, does $2.3B deal with Parabilis

BioWorld

Regeneron Pharmaceuticals Inc. stuck with the tradition of releasing bad news on Friday afternoon and good news on Monday morning with a pair of announcements...